en · de · es · pt
aod-9604-notes.peptides6608.com › Guide › Regulatory And Analytical Context — Common Mistakes

Regulatory And Analytical Context — Common Mistakes

By Editorial Desk · published 2026-06-18 · last reviewed 2026-07-06 · Guide

AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-07-06. Where a claim depends on a specific study, the study is described rather than over-claimed.

Regulatory and Analytical Context

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Aod-9604 at a glance

PropertyValueNotes
Regulatory statusNot approved as a medicineStatus varies by country; prohibited in sport.
Common storage temperature2–8 °C for lyophilized powderProtect from light and moisture; follow supplier instructions.
Typical analytical methodLC-MS/MSUsed for identification and quantification in biological samples.
Purity assessmentHPLC and mass spectrometryReverse-phase HPLC is common for peptide purity.
Common synonymsAOD9604; hGH 176-191 fragmentNaming conventions differ across studies.

Research and Regulatory Context

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.

Related pages on this site

Regulation and Detection Context

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.

Identity and Research Context

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Background from the literature

When Charles arrives in London as a prospective client, Yasmin uncovers that his finances are collapsing due to NDA settlements with former mistresses, including her childhood nanny. Yasmin confronts him over his predatory behavior, leading to Charles cutting her off financially. In series 3, Yasmin confronts Charles aboard his yacht in Mallorca after catching him having sex with an employee; after a vicious argument, he jumps overboard and drowns while she makes no attempt to save him, with Harper helping cover up her involvement. Back in London, Yasmin is hounded by press amid revelations of Charles’ embezzlement and subsequent disappearance. Working on the merged CPS/FX desk, she helps rescue the spiraling Lumi IPO and begins a relationship with CEO Henry Muck, which she ends after learning of his harassment of employees. After rejecting Eric’s advances and being betrayed by Harper in a short against Pierpoint, Yasmin is fired following the leak of images of her father’s corpse. During a visit to Henry’s estate, Yasmin and Robert finally have sex and confess their love, but Yasmin ultimately agrees to marry Henry for protection and security. Months on, Yasmin’s public image has recovered, and she and Harper have reconciled. In series 4, Yasmin reinvents herself as a socialite and political power broker as her marriage to Henry deteriorates following his loss of his parliamentary seat. She secures Henry the CEO role at fintech firm Tender and builds ties with Labour MP Jennifer Bevan to aid the company’s regulatory ambitions.

In 2000, Wesley Enoch wrote and directed a modern adaptation titled Black Medea, which was first produced by Sydney Theatre Company's Blueprint at the Wharf 2 Theatre, Sydney, on 19 August 2000. Nathan Ramsay played the part of Jason, Tessa Rose played Medea, and Justine Saunders played the Chorus. Medea is re-characterised as an indigenous woman transported from her homeland to the city and about to be abandoned by her abusive social-climbing husband. Tom Lanoye (2001) used the story of Medea to bring up modern problems (such as migration and man vs. woman), resulting in a modernized version of Medea. His version also aims to analyze ideas such as the love that develops from the initial passion, problems in the marriage, and the "final hour" of the love between Jason and Medea. Roger Kirby's 2004 adaptation of the play, Medea in Jerusalem, was set in modern day Israel, and featured an Israeli-Jewish Jason and a Palestinian Medea who opts to turn her children into suicide bombers after being divorced by Jason. It premiered at the Rattlestick Playwrights Theatre in New York City. Kristina Leach adapted the story for her play The Medea Project, which had its world premiere at the Hunger Artists Theatre Company in 2004 and placed the story in a modern-day setting. Peter Stein directed Medea in Epidaurus 2005. Irish playwright Marina Carr's By the Bog of Cats is a modern re-telling of Euripides' Medea. In November 2008, Theatre Arcadia, under the direction of Katerina Paliou, staged Medea at the Bibliotheca Alexandrina (University of Alexandria, Egypt).

gestational diabetes. This temporary form of diabetes appears during pregnancy, and with glucose-controlling medication or insulin symptoms can be improved. type 1 and type 2 diabetes or prediabetes. If diagnosed with diabetes, regular glucose tests can help manage or maintain conditions. Type 1, is commonly seen in children or teenagers whose bodies are not producing enough insulin. Type 2 diabetes, is typically seen in adults who are overweight. The insulin in their bodies are either not working normally, or there is not being enough produced. Low blood sugar may indicate

Sources: en.wikipedia.org

Reference notes

The team is commonly known as Los Cafeteros ("The Coffee Growers"), after Colombia's coffee industry, and as La Tricolor, after the yellow, blue and red of the national flag. The Colombian state broadcaster's archive service has described the shirt as having become "a new national symbol", worn across regions and social classes on match days. Colombia's yellow shirt, blue shorts and red socks are a relatively recent settlement rather than an inherited palette. Early sides alternated white and blue, with white worn at the 1945 South American Championship and dark blue at the 1962 FIFA World Cup. From 1971 the team wore orange, known domestically as zapote. In 1985 the Colombian Football Federation commissioned the designer María Elvira Pardo to base a kit on the national flag; her design made red the first-choice shirt, worn through the 1990 FIFA World Cup, with yellow as the alternative. Yellow was promoted to first choice in the early 1990s. Subsequent departures have been tournament-specific: a red change kit at the 2014 FIFA World Cup referencing the 1990s alternates, and a white first-choice shirt at the Copa América Centenario echoing the 1945 side. Adidas has supplied the team since January 2011 under an agreement signed in November 2010, subsequently extended to 2030; earlier suppliers included Le Coq Sportif, Adidas, Puma, Kelme, Umbro, Reebok and Lotto.

==== Biological oxidation and carcinogenic activity ==== One way of understanding the carcinogenic effects of benzene is by examining the products of biological oxidation. Pure benzene, for example, oxidizes in the body to produce an epoxide, benzene oxide, which is not excreted readily and can interact with DNA to produce harmful mutations.

=== Active enzyme === The binding energy of the enzyme-substrate complex cannot be considered as an external energy which is necessary for the substrate activation. The enzyme of high energy content may firstly transfer some specific energetic group X1 from catalytic site of the enzyme to the final place of the first bound reactant, then another group X2 from the second bound reactant (or from the second group of the single reactant) must be transferred to active site to finish substrate conversion to product and enzyme regeneration. We can present the whole enzymatic reaction as a two coupling reactions:

In fact, as revealed by the documentary, many men within the Mexican-American community considered women who received sterilizations as “mujeres de la calle”; wanton street walkers who wanted to sleep with multiple men at the same time. Such a reaction from their male counterparts had harmful effects on immigrant mothers. Maria Figueroa was barred from testifying in the lawsuit by her husband, and even attempted suicide in the aftermath of losing the ability to bear children. Gendered issues of bodily autonomy and sexual power relations were also a concern amongst Mexican-American women advancing the Chicano Student Movement. A lack of reproductive health counseling on college campuses contributed to the increasing dropout rates amongst Chicana students. Unplanned pregnancies and little to no access to birth control barred Chicana students from completing their undergraduate studies, though they tended to excel academically. There was also a general sense of skepticism amongst Mexican-American families about sending their children to American universities, as children were culturally expected to economically support their loved ones. Young Mexican-American women would also be expected to help raise their siblings—not have kids of their own just yet. Such a phenomenon across college campuses reflected a common double standard; Chicanos could enjoy their sexual freedom while assuming leadership positions in student activist groups while Chicana students were limited to supplemental roles in the movement and obligated to bear the brunt of an unplanned pregnancy.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 approved for medical use?

No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.

Why is it banned in sports?

The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.

How is AOD-9604 detected?

Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.

What is AOD-9604?

It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.

Network